Who
Anish Patel
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Enliven Therapeutics.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $7.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2023
- Last trade
- 12 Feb 2026
- Last filed
- 17 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M48,057 at $27.98 | filing |
| 9 Jan 2026filed 13 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,926243 at $28.50 | filing |
| 9 Jan 2026filed 13 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M48,057 at $27.98 | filing |
| 9 Jan 2026filed 13 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,926243 at $28.50 | filing |
| 8 Dec 2025filed 10 Dec 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K4,958 at $20.76 | filing |
| 8 Dec 2025filed 10 Dec 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,705 at $21.78 | filing |
| 7 Nov 2025filed 12 Nov 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $105K6,054 at $17.35 | filing |
| 7 Nov 2025filed 12 Nov 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K613 at $17.94 | filing |
| 7 Oct 2025filed 9 Oct 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $134K6,667 at $20.10 | filing |
| 8 Sep 2025filed 10 Sep 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $135K6,667 at $20.24 | filing |
| 7 Aug 2025filed 11 Aug 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $114K6,262 at $18.20 | filing |
| 7 Aug 2025filed 11 Aug 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,667405 at $18.93 | filing |
| 7 Jul 2025filed 9 Jul 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $126K6,362 at $19.75 | filing |
| 7 Jul 2025filed 9 Jul 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,310305 at $20.69 | filing |
| 9 Jun 2025filed 11 Jun 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $134K6,607 at $20.33 | filing |
| 9 Jun 2025filed 11 Jun 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,27060 at $21.16 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Anish Patel; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.